Alliances and partnering opportunities

PCI is leveraging its lead compound, Amphinex to induce photochemical internalization (PCI) of chemotherapeutic agents in localized cancers. PCI is the process of using light to induce direct delivery of active molecules (small, protein, antibodies, oligonucleotides and ADCs) to its target within the cell.

The PCI technology, including our lead product Amphinex, uniquely positioned for the enhancement of endocytosic drug delivery of compounds has been developed at the Institute of Cancer Research at the Norwegian Radium Hospital, the largest centre for cancer research and cancer treatment in Northern Europe. Amphinex and PCI are protected by an extensive patent estate including composition of matter on Amphinex and all intellectual property rights belong to PCI Biotech.

PCI Biotech is interested in engaging partnering discussions with parties that are developing pharmacological modalities that could benefit from an increased efficacy due to Amphinex-induced endosomal escape, from antibody-drug conjugate and siRNA to therapeutic vaccines.

For any partnering inquiries please contact: